A study of a GLP-1 medicine, semaglutide, in people with mild autonomous cortisol secretion (MACS).

Recruiting now. Registry record last updated March 27, 2026.

Who can join: Adults 18+, have mild autonomous cortisol secretion (MACS), BMI 27+.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 4 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Not ApplicableSponsor University of Texas Southwestern Medical CenterDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 75

What this study is for

Primary condition: Mild Autonomous Cortisol Secretion (MACS). Also studied in: Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess.

Full scientific study title: IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have mild autonomous cortisol secretion (MACS), BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Adults ≥18 years
MACS groups: adrenal adenoma + DST cortisol \>1.8 µg/dL + no overt Cushing + eligible for adrenalectomy
Willingness to postpone surgery 6 months if randomized
Controls: no adrenal abnormalities + normal DST + BMI ≥27 + ≥2 cardiometabolic conditions
Stable medication doses for ≥4 weeks

Key exclusion criteria

Prior GLP-1 RA within 90 days
Weight change \>5 kg in past 90 days
Prior obesity/diabetes surgery
Type 1 diabetes or other diabetes types
Severe organ disease

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Texas1 site

University of Texas Southwestern Medical Center
Dallas, Texas
Oksana Hamidi, DO, MSCS2146456397oksana.hamidi@utsouthwestern.edu

Follow this trial

We email you if NCT07361874 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: March 5, 2026. Expected completion: May 31, 2030. Last updated on ClinicalTrials.gov: March 27, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.